PPARs: Therapeutic targets for metabolic disease

Trends in Pharmacological Sciences

Volumn 26, Issue 5, 2005, Pages 244-251

  Berger, Joel P ^a   Akiyama, Taro E ^a   Meinke, Peter T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 5 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL) 2 HYDROXYETHOXY]BENZYL] 2,4 THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; COMPOUND 24; COMPOUND 48; FK 614; LY 510929; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; SIMVASTATIN; TESAGLITAZAR; TZD 18; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOSENSOR; BLOOD TOXICITY; CARDIOMEGALY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG TARGETING; EDEMA; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMODILUTION; HUMAN; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 18044376795     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.03.003     Document Type: Review

References (87)

1. J. Berger, and D.E. Moller The mechanism of action of PPARs Annu. Rev. Med. 53 2002 409 435
2. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
3. J. Plutzky The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis Am. J. Cardiol. 92 2003 34J 41J
4. R.M. Evans PPARs and the complex journey to obesity Nat. Med. 10 2004 355 361
5. L. Fajas The organization, promoter analysis, and expression of the human PPARgamma gene J. Biol. Chem. 272 1997 18779 18789
6. P. Tontonoz Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor Cell 79 1994 1147 1156
7. W. He Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle Proc. Natl. Acad. Sci. U. S. A. 100 2003 15712 15717
8. Y. Barak PPAR gamma is required for placental, cardiac, and adipose tissue development Mol. Cell 4 1999 585 595
9. N. Kubota PPARγ mediates high fat diet-induced adipocyte hypertrophy and insulin resistance Mol. Cell 4 1999 597 609
10. E.D. Rosen PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro Mol. Cell 4 1999 611 617
11. L. Chao Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones J. Clin. Invest. 106 2000 1221 1228
12. A.L. Hevener Muscle-specific Pparg deletion causes insulin resistance Nat. Med. 9 2003 1491 1497
13. A.W. Norris Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones J. Clin. Invest. 112 2003 608 618
14. S.M. Rangwala, and M.A. Lazar Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol. Sci. 25 2004 331 336
15. H. Bays Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J. Clin. Endocrinol. Metab. 89 2004 463 478
16. A.B. Mayerson The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 51 2002 797 802
17. M. Bajaj Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364 1370
18. T. Kawai Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes Metabolism 48 1999 1102 1107
19. Y. Miyazaki Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2002 2784 2791
20. M. Laplante PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion Diabetes 52 2003 291 299
21. A. Okuno Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats J. Clin. Invest. 101 1998 1354 1361
22. G. Boden Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes Metabolism 52 2003 753 759
23. P. Arner Regional adipocity in man J. Endocrinol. 155 1997 191 192
24. R.A. Hegele PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy Diabetes 51 2002 3586 3590
25. D.B. Savage Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma Diabetes 52 2003 910 917
26. M.W. Rajala, and P.E. Scherer Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis Endocrinology 144 2003 3765 3773
27. A.H. Berg The adipocyte-secreted protein Acrp30 enhances hepatic insulin action Nat. Med. 7 2001 947 953
28. T. Yamauchi The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat. Med. 7 2001 941 946
29. T.P. Combs Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization Endocrinology 143 2002 998 1007
30. M. Bajaj Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients J. Clin. Endocrinol. Metab. 89 2004 200 206
31. H. Xu Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J. Clin. Invest. 112 2003 1821 1830
32. G.S. Hotamisligil Inflammatory pathways and insulin action Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3 2003 S53 S55
33. H. Ruan, and H.F. Lodish Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines Curr. Opin. Lipidol. 15 2004 297 302
34. A.C. Li Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 106 2000 523 531
35. Z. Chen Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL Arterioscler. Thromb. Vasc. Biol. 21 2001 372 377
36. W.A. Hsueh, and D. Bruemmer Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease Hypertension 43 2004 297 305
37. G. Chinetti PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat. Med. 7 2001 53 58
38. A. Chawla A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol. Cell 7 2001 161 171
39. T.E. Akiyama Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux Mol. Cell. Biol. 22 2002 2607 2619
40. M. Ricote The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
41. J.S. Welch PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Proc. Natl. Acad. Sci. U. S. A. 100 2003 6712 6717
42. U. Kintscher Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes Eur. J. Pharmacol. 401 2000 259 270
43. G. Chinetti Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages J. Biol. Chem. 273 1998 25573 25580
44. D. Bruemmer A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth Eur. J. Pharmacol. 466 2003 225 234
45. D. Bruemmer Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells Mol. Endocrinol. 17 2003 1005 1018
46. D. Bruemmer Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells Circ. Res. 93 2003 e38 e47
47. J. Minamikawa Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes J. Clin. Endocrinol. Metab. 83 1998 1818 1820
48. P. Libby Inflammation and atherosclerosis Circulation 105 2002 1135 1143
49. N. Marx Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler. Thromb. Vasc. Biol. 23 2003 283 288
50. J.K. Reddy, and T. Hashimoto Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system Annu. Rev. Nutr. 21 2001 193 230
51. S. Kersten Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting J. Clin. Invest. 103 1999 1489 1498
52. J. Plutzky Emerging concepts in metabolic abnormalities associated with coronary artery disease Curr. Opin. Cardiol. 15 2000 416 421
53. M.F. Linton, and S. Fazio Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk Curr. Atheroscler. Rep. 2 2000 29 35
54. N. Vu-Dac Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be attenuated by interaction of the peroxisome proliferator activated receptor with its response element J. Biol. Chem. 269 1994 31012 31018
55. N. Vu-Dac Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor J. Clin. Invest. 96 1995 741 750
56. H. Bays, and E.A. Stein Pharmacotherapy for dyslipidaemia - current therapies and future agents Expert Opin. Pharmacother. 4 2003 1901 1938
57. N. Marx Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Circ. Res. 94 2004 1168 1178
58. R. Ross Atherosclerosis-an inflammatory disease New Engl. J. Med. 340 1999 115 126
59. N. Marx PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 99 1999 3125 3131
60. K. Goya Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells Arterioscler. Thromb. Vasc. Biol. 24 2004 658 663
61. B. Staels Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators Nature 393 1998 790 793
62. G. Chinetti CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors Circulation 101 2000 2411 2417
63. H. Shu Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells Biochem. Biophys. Res. Commun. 267 2000 345 349
64. N. Marx PPARalpha activators inhibit tissue factor expression and activity in human monocytes Circulation 103 2001 213 219
65. B.P. Neve PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages Circulation 103 2001 207 212
66. Z. Israelian-Konaraki, and P.D. Reaven Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications Cardiology 103 2005 1 9
67. H.B. Rubins Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch. Intern. Med. 162 2002 2597 2604
68. G. Steiner Treating lipid abnormalities in patients with type 2 diabetes mellitus Am. J. Cardiol. 88 2001 37N 40N
69. M.D. Leibowitz Activation of PPARdelta alters lipid metabolism in db/db mice FEBS Lett. 473 2000 333 336
70. W.R. Oliver A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proc. Natl. Acad. Sci. U. S. A. 98 2001 5306 5311
71. T. Tanaka Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome Proc. Natl. Acad. Sci. U. S. A. 100 2003 15924 15929
72. Y.X. Wang Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity Cell 113 2003 159 170
73. Y.X. Wang Regulation of Muscle Fiber Type and Running Endurance by PPARd PLoS Biol. 2 2004 1532 1539
74. H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med. 351 2004 1106 1118
75. J.P. Berger Distinct properties and advantages of a novel peroxisome proliferator-activated receptor [gamma] selective modulator Mol. Endocrinol. 17 2003 662 676
76. K. Arakawa An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats Clin. Exp. Pharmacol. Physiol. 31 2004 8 13
77. C.P. Miller SERMs: evolutionary chemistry, revolutionary biology Curr. Pharm. Des. 8 2002 2089 2111
78. J.J. Acton 3rd Benzoyl 2-methyl indoles as selective PPARgamma modulators Bioorg. Med. Chem. Lett. 15 2005 357 362
79. H. Minoura Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614 Eur. J. Pharmacol. 494 2004 273 281
80. J.P. Van Wijk Thiazolidinediones and Blood Lipids in Type 2 Diabetes. A Summary Analysis Arterioscler. Thromb. Vasc. Biol. 7 2003 7
81. T.W. Doebber MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities Biochem. Biophys. Res. Commun. 318 2004 323 328
82. Q. Guo A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis Endocrinology 145 2004 1640 1648
83. Y. Xu Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists J. Med. Chem. 47 2004 2422 2425
84. H. Koyama (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents J. Med. Chem. 47 2004 3255 3263
85. B.D. Hegarty Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo-a study using the novel PPARalpha/gamma agonist tesaglitazar Endocrinology 145 2004 3158 3164
86. R. Chakrabarti Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models Br. J. Pharmacol. 140 2003 527 537
87. M.F. Saad Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm Diabetes Care 27 2004 1324 1329